What is KeyCorp’s Forecast for Repligen Q2 Earnings?

Repligen Corporation (NASDAQ:RGEN) – KeyCorp issued their Q2 2026 EPS estimates for Repligen in a note issued to investors on Monday, June 1st. KeyCorp analyst P. Knight anticipates that the biotechnology company will post earnings of $0.49 per share for the quarter. KeyCorp has a “Overweight” rating on the stock. The consensus estimate for Repligen’s current full-year earnings is $1.99 per share. KeyCorp also issued estimates for Repligen’s Q3 2026 earnings at $0.47 EPS, Q4 2026 earnings at $0.57 EPS and FY2026 earnings at $2.00 EPS.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The business had revenue of $194.26 million for the quarter, compared to analyst estimates of $192.05 million. During the same period in the previous year, the company earned $0.39 earnings per share. The business’s revenue for the quarter was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS.

A number of other brokerages have also weighed in on RGEN. Wells Fargo & Company dropped their price objective on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. JPMorgan Chase & Co. dropped their price objective on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Wolfe Research began coverage on shares of Repligen in a report on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 price objective on the stock. Weiss Ratings raised shares of Repligen from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, May 7th. Finally, Barclays boosted their price objective on shares of Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $164.64.

Repligen Price Performance

NASDAQ RGEN opened at $130.76 on Thursday. The firm’s fifty day simple moving average is $119.67 and its two-hundred day simple moving average is $138.16. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26. Repligen has a 12-month low of $100.99 and a 12-month high of $175.77. The firm has a market capitalization of $7.38 billion, a P/E ratio of 145.29, a P/E/G ratio of 2.51 and a beta of 1.09.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD lifted its position in Repligen by 31.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock valued at $753,603,000 after purchasing an additional 1,091,683 shares during the period. United Capital Financial Advisors LLC acquired a new position in Repligen during the third quarter valued at $368,387,000. Opti Capital Management LP acquired a new position in Repligen during the fourth quarter valued at $2,399,209,000. Maverick Capital Ltd. acquired a new position in Repligen during the first quarter valued at $178,946,000. Finally, Holocene Advisors LP lifted its position in Repligen by 47.0% during the third quarter. Holocene Advisors LP now owns 1,377,104 shares of the biotechnology company’s stock valued at $184,077,000 after purchasing an additional 440,290 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.